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Abstract
Introduction: Total pancreatectomy (TP) is associated with significant metabolic abnormalities leading
to considerable morbidity. With the availability of modern pancreatic enzyme formulations and improve-
ments in control of diabetes mellitus, the metabolic drawbacks of TP have diminished. As indications for
TP have expanded, we examine our results in patients undergoing TP.
Materials and methods: Retrospective study of 47 patients undergoing TP from January 2002 to
January 2008 was performed. Patient data and clinical outcomes were collected and entered into a
database. Disease-free survival and overall survival were estimated using the Kaplan–Meier method.
Results: Fifteen males and 32 females with a median age of 70 years underwent TP for non-invasive
intraductal papillary mucinous neoplasms (IPMN) (21), pancreatic adenocarcinoma (20), other neoplasm
(3), chronic pancreatitis (2) and trauma (1). Median hospital stay and intensive care stay were 11 days and
1 day, respectively. Thirty-day major morbidity and mortality was 19% and 2%, respectively. With a
median follow-up length of 23 months, 33 patients were alive at last follow-up. Estimated overall survival
at 1, 2 and 3 years for the entire cohort was 80%, 72% and 65%, and for those with pancreatic
adenocarcinoma was 63%, 43% and 34%, respectively. Median weight loss at 3, 6 and 12 months after
surgery was 6.8 kg, 8.5 kg and 8.8 kg, respectively. Median HbA1c values at 6, 12 and 24 months after
surgery were 7.3, 7.5 and 7.7, respectively. Over one-half of the patients required re-hospitalization within
12 months post-operatively.
Conclusion: TP results in significant metabolic derangements and exocrine insufficiency, diabetic
control and weight maintenance remain a challenge and readmission rates are high. Survival in those with
malignant disease remains poor. However, the mortality appears to be decreasing and the morbidities
associated with TP appear acceptable compared with the benefits of resection in selected patients.
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Introduction
Total pancreatectomy (TP) was first successfully performed by
Priestley in 19441 for a patient with a non-localizable symptomatic
insulinoma. In the ensuing decades, the enthusiasm for TP for
malignant disease varied and was mostly performed in those with
pancreatic adenocarcinoma. In the 1970s, as a result of the signifi-
cant morbidity of a subsequent pancreatic fistula, concerns about
multicentric pancreatic cancer and theoretical survival benefits
with an extended lymphadenectomy, TP became a more accepted
option over partial pancreatic resection in selected patients.2–4
However, more recent data from polymerase chain reaction
(PCR) studies of pancreatic cancer specimens have indicated that
multicentric pancreatic cancer may not be as common as once
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thought,5 and that survival is not improved by TP over partial
pancreatectomy.6 Furthermore, recent experience indicates im-
proved outcomes and decreased surgical morbidity with partial
pancreatectomy over TP for malignancy.7
Most recently, there has been a renewed interest in TP as an
option in benign pancreatic disease8 and again in select malignant
disease. Since the description of intraductal papillary mucinous
neoplasms (IPMN) in 1982,9 there has been an increased use of TP
as a treatment for diffuse pancreatic involvement of this prema-
lignant lesion.10–15 Furthermore, recognition of familial pancreatic
cancer syndromes has only recently been appreciated, leading to
more aggressive approaches including TP in those patients with
genetic abnormalities.16 For these reasons, there has been an
increased utilization of TP. According to a surveillance epide-
miology and end results (SEER) database review, the percentage
of TP performed compared with partial pancreatectomy for pan-
creatic adenocarcinoma has risen from 9.3% of patients in 1998
to 14.3% of patients in 2004.17
TP remains a significant undertaking and is associated with
major metabolic abnormalities such as difficulties in glucose
control and malabsorption leading to multiple medical problems
and decreased quality of life.18 However, with the availability of
modern pancreatic enzyme formulations and improvements in
control of diabetes mellitus, the metabolic drawbacks of TP may
have diminished from historic controls. Recognizing the recent
increased utilization of TP as well as improved diabetic manage-
ment tools in the recent decade, the aim of this study was to review
our experience with TP and report the outcomes.
Materials and methods
This retrospective study was conducted in accordance with the
Helsinki Declaration. After the study had been approved by the
Mayo Clinic Institutional Review Board (registration 08000743;
4 March 2008), all patients undergoing pancreatic resection
between January 2002 and January 2008 were identified and the
subgroup undergoing TP was reviewed in detail.
Data collected included: patient demographics, presenting
clinical features, operative and pathological details, peri-operative
outcomes and long-term outcomes. Follow-up was obtained
through internal and external medical records and patient inter-
view. If no follow-up could be attained, the national social security
index was searched for date of death.
Pathology data on pancreatic tumour staging were collected
according to the tumor, node, metastases (TNM) staging system.
IPMN pathology was described as per WHO criteria. Pancreatic
adenocarcinoma arising in the background of IPMN was consid-
ered to have arisen from premalignant IPMN, whereas pancreatic
adenocarcinoma specimens without any evidence for IPMN were
considered as pancreatic adenocarcinoma de novo.
Operative strategy
In this series, TP was performed in a standard open fashion,
adhering to oncological principles when appropriate.19 The
abdomen was explored for occult metastatic disease and the
tumour assessed for resectability. TP was performed with both
pylorus preserving and standard technique as well as with and
without the spleen sparing technique. If a partial pancreatic
resection was attempted, the pancreatic margin was analysed by
frozen section. If found to be involved with invasive carcinoma,
further margins were analysed and completion TP was per-
formed if multiple margins were involved and the patient was felt
to be able to tolerate a TP. Generally, further margin analysis with
conversion to completion TP was performed for pancreatic
margins found to have carcinoma in situ or severe dysplasia,
especially in a young fit patient. Commonly, further margin
analysis or completion TP were not performed for findings of
moderate dysplasia or adenomatous changes for patients under-
going pancreatic resection.
Post-operative complications were graded according to
methods previously described20 and limited to complications seen
within 30 days of surgery or within the index hospitalization. A
score of 0–5 was assigned based on the most severe post-operative
complication experienced by each patient. Grade 0 indicates no
complications were recorded. Grade 1 indicates minor complica-
tions requiring observation or minor outpatient intervention (e.g.
oral antibiotics). Grade 2 indicates complications requiring mod-
erate intervention (e.g. wound debridement, intravenous anti-
biotics). Grade 3 indicates major intervention (e.g. CT-guided
drainage of intra-abdominal fluid collection, surgery). Grade 4
indicates permanent disability (e.g. stroke with residual paresis
or paralysis, chronic ventilator dependence) or discharge to
long-term care facility. Grade 5 indicates death. Grade 1 and 2
complications were considered minor and Grade 3, 4 and 5
complications were consideredmajor. Complications were further
differentiated into ‘medical’ and ‘surgical’ complications and
recorded in addition to graded complications to fully characterize
their nature. International consensus guidelines were used to
evaluate complications when available.21,22
Numerical variables were summarized with the sample median,
minimum and maximum. Categorical variables were summarized
with number and percentage. The Kaplan–Meier method was
used to estimate overall survival and disease-free survival after
surgery.Weight loss after surgery was compared according to pres-
ence of pylorus preserving using a Wilcoxon rank sum test.
P-values 0.05 were considered statistically significant. Statistical
analyses were performed using the SAS software package (SAS
Institute; Cary, NC, USA).
Results
From January 2002 to January 2008, a total of 397 pancreatic
resections were performed. These included: 234 (59%) proximal
pancreatectomies (pancreaticoduodenectomies), 116 (29%) distal
pancreatectomies and 47 (12%) TPs. The 47 patients undergoing
TP [32 females, median age of 70 (range 32–83)] were included in
the study.
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Patient characteristics
Pre-operative patient demographics and clinical characteristics
are presented in Table 1a. Table 1b shows pre-operative symp-
toms. Abdominal pain was the most common presenting
symptom and nearly half of the patients experienced a median
weight loss of 9 kg.
Indications for surgery and operative data
Portal vein resection was carried out in 10 (21%) patients and
pylorus preservation in 23 (49%).Median estimated blood losswas
800 ml (range 195–7800), median operative time was 396 min
(range 232–553) and median number of intra-operative packed
red blood cell transfusions was 3 units (range 0–22). Spleen pres-
ervation techniquewas carried out in 13 (28%).Three patients had
undergone a previous partial pancreatic resection and were found
to have indications for an elective completionTP at 1, 4, and 6 years
from previous distal pancreatectomy for neuroendocrine tumour,
pancreaticoduodenctomy for pancreatic adenocarcinoma and
distal pancreatectomy for chronic pancreatitis, respectively.
Pathology
Pathology finding are shown in Table 2a. Twenty-three patients
(49%) had malignant findings with the majority (n = 20, 87%)
having pancreatic adenocarcinoma. Among patients with pancre-
atic adenocarcinoma, 10 (50%) were found to arise de novo,
whereas the remaining 10 (50%) were found to arise in the back-
ground of IPMN. Table 2b displays tumour staging information
in the pancreatic adenocarcinoma patients. Those patients with
pancreatic adenocarcinoma arising de novo were generally seen at
a higher stage with larger tumour size. Five patients with R1
positive margins included an uncinate process/superior mesen-
teric artery positive margin in two, superior mesenteric vein posi-
tive margin in two and radial positive margin in one. One patient
underwent R2 resection with gross residual disease involving the
superior mesenteric artery.
Table 1a Patient characteristics
Variable All patients
(n = 47)
Pancreatic
adenocarcinoma
de novo (n = 10)
Pancreatic
adenocarcinoma
from IPMN (n = 10)
Non-invasive
IPMN (n = 21)
Age 70 (32, 83) 70 (58, 83) 71 (57, 78) 71 (43, 78)
Gender (male) 15 (32%) 5 (50%) 4 (40%) 4 (19%)
BMI 26 (18, 43) 25 (18, 33) 27 (21, 33) 27 (19, 43)
CA 19-9 (U/ml) 40 (1, 11841) 408 (1, 6284) 203 (1, 11841) 21 (1, 60)
ASA class
2 15 (32%) 3 (30%) 1 (10%) 10 (48%)
3 27 (57%) 6 (60%) 6 (60%) 10 (48%)
4 5 (11%) 1 (10%) 3 (30%) 1 (5%)
Diabetes
Long standing 11 (23%) 2 (20%) 4 (40%) 4 (19%)
Recent onset 6 (13%) 2 (20%) 1 (10%) 2 (10%)
Insulin-dependant 4 (9%) 0 (0%) 2 (20%) 1 (5%)
Hypertension 29 (62%) 6 (60%) 8 (80%) 11 (52%)
CAD 13 (28%) 5 (50%) 3 (30%) 5 (24%)
COPD 5 (11%) 0 (0%) 1 (10%) 4 (19%)
ETOH 26 (55%) 4 (40%) 6 (60%) 12 (57%)
Pancreatitis 11 (23%) 1 (10%) 2 (20%) 7 (33%)
Length of follow up (y) 1.9 (0.0, 4.9) 0.8 (0.0, 2.8) 1.3 (0.2, 3.9) 2.5 (0.2, 4.9)
The sample median (minimum, maximum) is given for numerical variables. Information was unavailable for the following variables: weight loss at
surgery (n = 2), and CA 19-9 (n = 8).
IPMN, intraductal papillary mucinous neoplasms; BMI, body mass index; ASA, American Society of Anesthesia; CAD, coronary artery disease; COPD,
chronic obstructive pulmonary disease; ETOH, alcohol use.
Table 1b Patient pre-operative symptoms
Variable Summary
(n = 47)
Abdominal pain 33 (70%)
Weight loss 21 (47%)
Median (minimum, maximum) weight loss (kg) 9 (3–34)
Jaundice 14 (30%)
Nausea/vomiting 7 (15%)
Diarrhoea 7 (15%)
Early satiety 4 (9%)
Asymptomatic 3 (6%)
Other 3 (6%)
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Among the 24 (51%) patients with benign pathology, 21 (88%)
had non-invasive IPMN (Table 2c). The median time from diag-
nosis of IPMN to surgery was 5 months (range 2–120), and the
most common reason for TP was planned procedure for diffuse
disease (n = 15, 71%). When considering the entire cohort of 47
TPs, IPMN was seen in 32 (68%) of the resected specimens. Of
these, according to the WHO classification system, 11 patients
(34%) had simple adenoma, 1 patient (3%) had low-moderate
dysplasia, 10 patients (31%) had high-grade dysplasia and 10
patients had invasive adenocarcinoma (31%).
Table 2a Indications for total pancreatectomy (TP)
Summary
(n = 47)
Malignant 23 (49%)
Pancreatic adenocarcinoma 20 (43%)
Pancreatic adenocarcinoma de novo 10 (21%)
Pancreatic adenocarcinoma with underlying IPMN 10 (21%)
Cholangiocarcinoma with IPMN 1 (2%)
Neuroendocrine tumour 1 (2%)
Renal cell carcinoma 1 (2%)
Non-malignant 24 (51%)
Non-invasive IPMN 21 (45%)
Chronic pancreatitis 2 (4%)
Trauma 1 (2%)
IPMN, intraductal papillary mucinous neoplasms.
Table 2c Characteristics of intraductal papillary mucinous neoplasm
(IPMN) lesions
Summary
(n = 21)
WHO classification
High grade (CISa) 10 (48%)
Low-moderate (Borderine) 1 (4%)
None (adenoma) 10 (48%)
Reason for total pancreatectomy
Diffuse involvement 15 (71%)
Positive margins 5 (24%)
Completion 1 (5%)
Disease duration (months) 5 (2, 120)
a Carcinoma in situ.
The sample median (minimum, maximum) is given for disease duration.
Table 2b Tumour information in pancreatic adenocarcinoma patients
Variable Pancreatic
adenocarcinoma
(n = 20)
Pancreatic
adenocarcinoma
de novo (n = 10)
Pancreatic
adenocarcinoma
from IPMN (n = 10)
Tumour grade
1 3 (15%) 0 (0%) 3 (30%)
2 10 (50%) 6 (60%) 4 (40%)
3 7 (45%) 4 (40%) 3 (30%)
Tumour stage
IA 1 (5%) 0 (0%) 1 (10%)
IIB 2 (10%) 1 (10%) 1 (10%)
IIA 4 (20%) 0 (0%) 4 (40%)
IIB 11 (55%) 7 (70%) 4 (40%)
III 2 (10%) 2 (20%) 0 (0%)
Positive lymph nodes 13 (65%) 9 (90%) 4 (40%)
Lymphatic invasion 17 (85%) 9 (90%) 8 (80%)
Positive margins 6 (30%) 4 (40%) 2 (20%)
Tumour size (cm) 3.5 (0.8, 7.0) 3.9 (2.5, 7.0) 2.2 (1.0, 7.0)
Reason for total pancreatectomy
Diffuse involvement 9 (45%) 4 (40%) 5 (50%)
Positive neck margins 9 (45%) 5 (50%) 4 (40%)
Familial syndrome 1 (5%) 0 (0%) 1 (10%)
Completion 1 (5%) 1 (10%) 0 (0%)
The sample median (minimum, maximum) is given for tumour size. Information was unavailable for positive lymph nodes (n = 1) and lymphatic invasion
(n = 2).
IPMN, intraductal papillary mucinous neoplasms.
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Survival and disease recurrence
With a median length of follow-up of 23 months (range 0.5–59)
after pancreatectomy, 14 patients (30%) had died. Estimated
patient survival after TP according to disease pathology is dis-
played in Table 3 and Fig. 1. Overall, 65% (95% CI: 18–51%) of
patients were still alive at 3 years after TP; this estimated rate was
95% (95% CI: 85–100%) in non-invasive IPMN patients, 34%
(95% CI: 17–70%) for all pancreatic adenocarcinoma, 49% (95%
CI: 20–100%) in patients with pancreatic adenocarcinoma from
IPMN and 0% (95% CI: 0–37%) in patients with pancreatic
adenocarcinoma de novo. There were nine deaths within 1 year
of pancreatectomy, and five were related to cancer recurrence. Of
the four deaths not related to cancer, two deaths were caused by
medical deconditioning related to total pancreatectomy at 0.5 and
11.4 months, and two were not related to total pancreatectomy
or cancer. One patient expired from a mycotic abdominal aortic
aneurysm at 5.7 months and another developedmetastatic Merkel
cell cancer and died at 8.9 months. Of the five remaining deaths
occurring after 1 year of surgery, four were related to cancer recur-
rence and one was related to medical deconditioning related to
TP at 25 months.
Estimated disease-free survival after TP for pancreatic adeno-
carcinoma is shown in Table 4 and Fig. 2. At a median time
follow-up of 30 months (range 2–59), none of the 21 non-invasive
IPMN patients had experienced disease recurrence. For all pan-
creatic adenocarcinoma patients, estimated disease-free survival
at 3 years after total pancreatectomy was 16% (95% CI: 3–85%),
but was slightly higher in patients with pancreatic adenocarci-
noma from IPMN (35%, 95% CI: 8–100%) than in patients with
pancreatic adenocarcinoma de novo (0%, 95% CI: 59–100%).
Other patient outcomes
Table 5a summarizes other patient outcomes after TP. The median
length of intensive care unit stay was 1 day, whereas the median
length of hospital stay was 11 days. During their hospital stay, 8
patients required supplemental parenteral nutrition for a median
of 7 days (range 3–37). No complications were seen in 25 patients
(53%), minor complications in 13 (28%) and major complica-
tions in 9 (19%). There were 12 (26%) medical complications and
17 (36%) surgical complications in 22 patients, with 7 patients
(15%) experiencing both. Four patients (9%) required reopera-
tion and there was one mortality. All reoperations were performed
for post-operation intra-abdominal abscess with findings of
colonic fistula in two (one patient underwent concomitant colon
resection and TP), gastrojejunostomy breakdown in one and
biliary peritonitis in one. The mortality was in a 68-year-old mor-
bidly obese, malnourished woman with chronic deep vein throm-
bosis who had locally advanced pancreatic cancer and underwent
TP with portal vein resection. After surgery, she had continued
malnourishment and deconditioning and discharged home after a
9-day hospital stay. Eight days later, she presented to an outside
institution with severe dehydration and hyperglycaemia and
expired.
Forty-three patients (92%) were placed on an insulin drip post-
operatively for a median of 6 days (range 0–18). Most patients
were maintained on an insulin drip until tolerating an oral diet,
which was then transitioned to a long-acting injectable insulin
glargine in addition to a sliding scale of short-acting injectable
insulin. All patients were seen by our inpatient diabetic education
and nutrition management team. The median dose of long-acting
insulin glargine at discharge was 10 units (range 0–80).
Median weight loss at 3, 6 and 12 months after surgery was 6.8,
8.5 and 8.8 kg, respectively, and did not differ dramatically
Figure 1 Estimated survival after total pancreatectomy according to
underlying disease
Table 3 Estimated survival after total pancreatectomy (TP) according to underlying disease
Time after
surgery
Estimated survival (95% CI)
All patients
(n = 47)
Pancreatic
adenocarcioma
(n = 20)
Pancreatic
adenocarcinoma
de novo (n = 10)
Pancreatic
adenocarcinoma
from IPMN (n = 10)
Non-invasive
IPMN (n = 21)
6 months 93% (86–100%) 84% (70–100%) 80% (59–100%) 89% (71–100%) 100% (83–100%)
1 year 80% (68–92%) 63% (55–89%) 40% (19–85%) 89% (71–100%) 95% (85–100%)
2 years 72% (59–87%) 43% (24–76%) 30% (12–77%) 49% (20–100%) 95% (85–100%)
3 years 65% (49–82%) 34% (17–70%) 0% (0–37%) 49% (20–100%) 95% (85–100%)
IPMN, intraductal papillary mucinous neoplasms.
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between patients with and without pylorus preserving at any post-
operative time point considered (all P > 0.35).
From the date of discharge, 12 out of the 46 patients (26%)
available for follow-up required rehospitalization within 1 month
of discharge.Of the 42 patients available for follow-up at 1 year, 23
(55%) required hospitalization within 12 months of discharge.
The 23 patients hospitalized within 12 months experienced a total
of 45 admissions, and 42 (93%) of these rehospitalizations were
successfully treated and discharged without complications. The
median length of stay for rehospitalization was 6 days (range
1–56). This and other rehospitalization information is displayed
in Table 5b.
Discussion
TP appears to be increasingly accepted for selected pancreatic
pathologies. In the first half of our study period, 8.3% (n = 12) of
all pancreatic resections performed at our institution were TP,
whereas in the second half, the rate more than doubled to 17.4%
(n = 35), even without any variation in the underlying disease
pathology between the two time periods. In fact, there were no
TPs performed from the years 2000 to 2002 at our institution.
While the reason for the increased frequency of TP is not entirely
clear based on the retrospective nature of our review, there are
several reasons found in the literature and confirmed in our
cohort which may account for this finding.
The first reason may be that surgeons, gastroenterologists and
endocrinologists alike may be more comfortable with the man-
agement of the apancreatic state that was so feared in the past. In
a study very similar to ours, Jethwa et al.23 reported that there were
no observed mortalities as a result of diabetic complications or
metabolic consequences of pancreatic resection during long-term
follow-up of 47 patients undergoing TP. They concluded that
diabetic control after TP is less difficult and associated with fewer
glycaemic complications than generally assumed. Similarly, in the
largest single institution review of 124 elective TPs, a group from
Germany found TP was performed with the same morbidity rate
as partial pancreatectomy, and quality of life was not significantly
different in the two groups.24 This confirmed a previous report
from 2005 where quality of life in 34 TP patients was compared
with matched type I diabetic controls, and no difference was
found.25 The improved overall results seen in the past decade over
historic reports may also be multifactorial. Improvements in
glucose monitoring systems, insulin delivery systems and insulin
formulations may contribute to superior glycaemic control for
these patients.26 The HbA1c levels seen in our patient series is very
reasonable for insulin-dependant diabetes and is comparable to
that seen in other recent reports.23–25,27 Our conclusion in this
study may be limited by the fact that the 29 patients for whom
HbA1c data were available were generally the healthiest patients
with benign disease. This introduces a bias by excluding those
with significant morbidities or those with a poor prognosis who
have a limited need for tight long-term glucose control for long-
term diabetic complication prevention.
In addition to improved endocrine control, exocrine insuffi-
ciency may be improved by modern pancreatic enzyme formula-
tions, proton pump inhibitor therapy and the use of the
duodenum-preserving pancreatic head resections. In a report
from Japan, the pylorus-preserving technique was noted to be
associated with significantly improved albumin levels and weight
loss over the standard TP.28 However, we did not find a significant
difference in weight loss between these two patient groups at any
point of follow-up. Weight loss continues to be problematic for
Table 4 Estimated cumulative rate of disease recurrence after pancreatectomy in patients with pancreatic adencarcinoma
Time after surgery Estimated disease-free survival (95% CI)
Pancreatic
adenocarcinoma
(n = 19)a
Pancreatic
adenocarcinoma
de novo (n = 9)a
Pancreatic
adenocarcinoma
from IPMN (n = 10)
6 months 77% (59–100%) 47% (21–100%) 100% (63–100%)
1 year 56% (26–87%) 16% (3–93%) 87% (67–100%)
2 years 31% (12–83%) 0% (0–41%) 70% (40–100%)
3 years 16% (3–85%) 0% (0–41%) 35% (8–100%)
aInformation regarding disease recurrence was unknown for one pancreatic adenocarcinoma de novo patient.
IPMN, intraductal papillary mucinous neoplasms.
Figure 2 Estimated disease-free survival after total pancreatectomy
according to underlying disease
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these patients as we found that nearly all patients experienced
continued steady weight loss in the months after TP, generally
plateauing at 12 months. This trend was true for all patient sub-
groups, and there were no differences between the patients with
malignant and benign disease. The reasons for this weight loss
were multifactorial and mostly attributed to failure to thrive as a
result of poor oral intake, malabsorption and diarrhoea, chronic
postprandial abdominal pain, cancer recurrence, or a combina-
tion of the prior for all patients despite pancreatic enzyme
replacement.
In addition to the improved long-term morbidity, another
explanation for the increased use of TP may be the improved
peri-operative mortality seen in recent years. Although histori-
cally reported to be a high-risk procedure, our experience and
recent literature are reporting a mortality rate of less than
5%,6,8,14,24,25,28 confirming that TP can be performed safely and that
overall survival is generally based on the underlying disease
process.
Another rationale for the increased rate of TP may be an
increased diagnosis of diffuse ductal disease in all patients under-
going pancreatic resection. Improved radiographic and endo-
scopic surveillance during preoperative testing as well as close
attention to intra-operative frozen section pathologic analysis of
the pancreatic duct margin may contribute to this. At our insti-
tution, magnetic resonance cholangiopancreatography and endo-
scopic ultrasound evaluation are common for evaluation of all
pancreatic masses and may increase the sensitivity for finding
ductal abnormalities at more diffuse locations than the primary
tumour. Intra-operative microscopic analysis of the pancreatic
margin is important as margin clearance and the risk of leaving
dysplastic or cancerous cells has been emphasized as important
predictors of recurrence and survival. A retrospective analysis of
33 patients with pancreatic adenocarcinoma undergoing conver-
sion to TP after findings of a positive margin during pancrea-
ticoduodenectomy conferred a significant survival benefit over
patients with an R1 resection.29 Recurrence after partial pan-
creatic resection for non-invasive IPMN is low but has been
reported to be as high as 8%.10,11,30 These recurrences may be the
result of a failure to diagnose diffuse main duct disease either by
pre-operative radiographic studies or by intra-operative micro-
scopical analysis. In our series, conversion to TP as a result of
positive margins was seen in 45% of all patients with pancreatic
Table 5a Patient outcomes
Variable Summary
(n = 47)
Length of hospital stay (days) 11 (7, 72)
Length of ICU stay (days) 1 (0, 12)
Supplemental parental nutrition 8 (17%)
Post-operative insulin drip 43 (47%)
Complication grade
0 25 (53%)
1 5 (11%)
2 8 (17%)
3 8 (17%)
4 0 (0%)
5 1 (2%)
Surgical complication 17 (36%)
Intra-abdominal abscess/sepsis 5 (11%)
Biliary/GI fistula 4 (9%)
Delayed gastric emptying 5 (11%)
Wound infection 7 (15%)
Reoperation 4 (9%)
Medical complication 12 (26%)
Gastritis/colitis 1 (2%)
Pulmonary 3 (6%)
Cardiac 2 (4%)
Thrombosis 1 (2%)
Glycaemic events (major) 2 (4%)
Renal insufficiency/urinary tract infection 3 (6%)
Weight loss (kg)
3 months after surgery -6.8 (-25.0, 12.1)
6 months after surgery -8.5 (-28.6, 2.4)
12 months after surgery -8.8 (-39.5, 1.2)
HbA1c
3 months after surgery 6.5 (4.6, 7.5)
6 months after surgery 7.3 (5.0, 9.6)
12 months after surgery 7.5 (5.2, 8.6)
24 months after surgery 7.7 (6.6, 8.8)
The sample median (minimum, maximum) is given for numerical vari-
ables. Information was unavailable for the following variables: weight loss
at 3 months after surgery (n = 4), weight loss at 6 months after surgery (n
= 15), weight loss at 1 year after surgery (n = 19), HbA1c at 3 months after
surgery (n = 34), HbA1c at 6 months after surgery (n = 31), HbA1c at 1
year after surgery (n = 28), and HbA1c at 2 years after surgery (n = 32).
Table 5b Rehospitalization information
Variable Summary
Rehospitalization by 1 month after discharge (n = 46) 12 (26%)
Rehospitalization by 4 months after discharge (n = 43) 20 (47%)
Rehospitalization by 12 months after discharge (n = 42) 23 (55%)
Reasons for re-hospitalization (n = 45 total
rehospitalizations)
Malnutrition/FTT/N/V/D/weakness 20 (44%)
Gastrointestinal even (e.g. GI bleed) 9 (20%)
Glycaemic events 5 (11%)
Infection 5 (11%)
Other 6 (13%)
The sample sizes given associated with rehospitalization indicate the
number of patients with a length of follow-up necessary to calculate the
given rehospitalization rate.
FTT, Failure to thrive; N, Nausea; V, Vomiting; D, Diarrhoea.
HPB 489
HPB 2009, 11, 483–492 © 2009 International Hepato-Pancreato-Biliary Association
adenocarcinoma and 24% of those with non-invasive IPMN.
However, because of the retrospective nature of this study and
the lack of pertinent data, we are unable to fully define or stan-
dardize each particular surgeon’s decision based on frozen
section analysis for each specific patient. Generally, however, in
all patients undergoing pancreatic resection, pancreatic margins
found to have frank carcinoma or high grade dysplasia of the
duct were considered for additional margin analysis or conver-
sion to TP.
Survival of patients undergoing TP varied tremendously in our
cohort between different patient groups and was generally as a
result of the underlying disease process, as demonstrated by the
similarity of the patient disease-free survival rates and the overall
survival rates. As expected, those with benign disease had very
good survival whereas those with invasive cancer had poor sur-
vival. This finding confirms multiple previous reports concerning
the difference in survival between those with invasive versus non-
invasive IPMN,10–12,14,31 as well as the difference in survival for
those with pancreatic cancer arising in the background of IPMN
versus sporadic pancreatic adenocarcinoma.32 Survival after TP
for pancreatic adenocarcinoma has in the past been reported to be
poor and some authors have questioned the value of the operation
in light of the significant metabolic consequences conferred to a
patient with a limited life span.4,6 However, it appears that the
3-year survival of those with pancreatic cancer from IPMN after
total pancreatectomy seen in our series compares to 3-year sur-
vivals seen in those reports for all of invasive IPMN’s undergoing
pancreatic resection.12,14,31 It remains to be seen whether TP in this
patient subgroup may improve survival over partial pancreatec-
tomy. Survival differences, specifically between those undergoing
partial pancreatic resection for pancreatic adenocarcinoma with
IPMN versus TP, remains unknown.
The poor survival experienced by those with pancreatic adeno-
carcinoma de novo can also be explained by the high rate of
positive lymph nodes (9 of 10), high positive margin rate (4 of
10), need for portal vein resection (4 of 10) and large tumour size
(median 3.9 cm) which indicates that most of these tumours
were locally advanced at the time of surgery and required com-
plete pancreas removal in an attempt to obtain an R0 resection.
Recurrence rates were also very high for all pancreatic adenocar-
cinoma for the same reasons as above. Site of recurrence was
difficult to determine for most patients as they were generally
found to have abdominal adenopathy as well as distant lesions
found at the same time on follow-up imaging. The value of con-
version to TP after attempted partial pancreatic resection with
intra-operative findings of a positive margin at a location other
than the pancreatic margin is debatable. In some cases, margins
originally reported as negative may turn out to be involved by
permanent section analysis, theoretically reducing the benefit of
a completion pancreatectomy. However, with the use of adjuvant
local radiation therapy, the extended survival advantage of an R1
over R2 resection may outweigh the metabolic consequences of
TP for selected patients.
The rehospitalization rate observed in this patient population is
very high and is even likely underestimated. The majority of these
patients live some distance from our institution and may present
to outside facilities for medical problems arising within a year
after discharge. Retrospective review of the available admission
data indicates that the majority could have been avoided with
improved preventive management. The significant metabolic
derangements of the apancreatic state may not become imme-
diately apparent in the post-operative inpatient recovery phase.
Most of these elderly patients do not have baseline endocrine or
exocrine insufficiency before surgery and have difficulty adjusting
to complex diabetic and nutritional changes seen after TP. Multi-
disciplinary management is mandatory for improved outcomes
and intensive diabetic and nutritional counselling are essential.
Providing extended care by discharge to a skilled nursing facility
with diabetic education and nutrition capabilities appears appro-
priate. Additionally, consideration should be given for providing
all patients with supplemental enteral feeding for several weeks
post-operatively. A strict follow-up protocol should be available
for these patients which includes close endocrine and nutrition
supervision, strict adherence to proton pump inhibitor (PPI) and
pancreatic enzyme replacement therapy and adequate hydration
and protein intake. These measures may avoid readmission in the
majority of the patients, particularly for the diagnosis of dehydra-
tion, diabetic complications and failure to thrive.
All patients who have undergone open or laparoscopic TP (n =
5) since the end of this study period have had enteral feeding tubes
placed during their index procedure. A patient pathway has been
developed and all patients will be followed. Those patients iden-
tified as likely to undergo TP are now enrolled into a series of
pre-operative education appointments which allow for diabetic
teaching to be performed in a setting more conducive to long-
term retention rather than that of the recovery phase in the hos-
pital. A primary coordinator is made available to manage insulin
adjustment difficulties with routine measurements of HbA1c at
intervals during the post-operative period. After surgery, frequent
weight measurements, serum protein levels, daily caloric intake
and the number of stools per day are also recorded at intervals in
order to determine nutritional adequacy.
Limitations in this study were related to the small sample size as
we were unable to find significant associations concerning patient
characteristics and pathology information with survival, recur-
rence or post-operative outcomes other than those expected to be
associated with poorer survival (higher tumour stage, positive
lymph nodes, lymphovascular invasion and more than three units
of blood transfused during the procedure). Other limitations of
this study included inadequate follow-up, as three patients were
lost within 2 months of the surgery, and short follow-up in others,
as well as incomplete data on the HbA1c values. Additionally, the
overall cohort was a heterogenous population undergoing total
pancreatectomy for a variety of disease states and was performed
by four different surgeons, introducing surgeon-specific bias and
perspective.
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Conclusion
TP for premalignant and malignant lesions will continue to have
a significant role in the treatment of pancreatic pathology.
However, TP results in significant metabolic derangements which
require multidisciplinary management for improved outcomes.
Diabetic control and weight maintenance remain a challenge.
Intensive diabetic and nutritional counselling combined with
advanced insulin formulations and delivery systems, pancreatic
exocrine formulations and vitamin supplementations are essen-
tial. Readmission rates and weight losses are significant and indi-
cate that these patients need rigorous outpatient observations and
provision of additional nutrition for an extended period of time.
Mortality and long-term morbidity associated with TP appear
to be lessening over the past decade, indicating that the risks of TP
appear acceptable compared with the benefits of resection, espe-
cially for those patients with premalignant disease. Overall, sur-
vival is generally based on the underlying disease process, not a
consequence of the surgery. However, because of our past results
we would hesitate in performing a TP on an elderly patient with
evidence of a locally advanced pancreatic tumour, as occurred in
our single mortality. Instead, TP may be a more practical proce-
dure for a young, motivated and educated patient who has diffuse
disease of the whole pancreas with early malignancy and main
duct IPMN or those with familial pancreatic cancer.
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